RepliCel Life Sciences Inc Stock Toronto S.E.
Equities
RP
CA76027P1036
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- CAD | - |
|
Sales 2022 | 354K 259K | Sales 2023 | 354K 259K | Capitalization | 3.87M 2.84M |
---|---|---|---|---|---|
Net income 2022 | - 0 | Net income 2023 | - 0 | EV / Sales 2022 | 9.26 x |
Net Debt 2022 | 300K 220K | Net Debt 2023 | 797K 584K | EV / Sales 2023 | 13.2 x |
P/E ratio 2022 |
-3.54
x | P/E ratio 2023 |
-11.3
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 39.48% |
Managers | Title | Age | Since |
---|---|---|---|
Andrew Schutte
CEO | Chief Executive Officer | 35 | 18-12-13 |
Rolf Hoffmann
FOU | Founder | 63 | - |
Kevin McElwee
FOU | Founder | 54 | - |
Members of the board | Title | Age | Since |
---|---|---|---|
David Hall
CHM | Chairman | 71 | 10-12-21 |
Peter Lewis
BRD | Director/Board Member | 69 | 11-05-26 |
Rolf Hoffmann
FOU | Founder | 63 | - |
1st Jan change | Capi. | |
---|---|---|
+20.12% | 126B | |
+25.25% | 119B | |
+25.56% | 27.95B | |
-19.51% | 20.5B | |
-14.36% | 17.12B | |
-15.63% | 16.1B | |
-46.67% | 14.97B | |
+11.89% | 14.84B | |
+57.74% | 14.38B |
- Stock Market
- Equities
- REPCF Stock
- RP Stock